Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fusion Antibodies Plc ( (GB:FAB) ) has issued an update.
Fusion Antibodies plc announced a conditional placing to raise approximately £1.17 million through the issuance of new ordinary shares. The funds will be used to enhance the company’s cash position, support research and development, and promote its OptiMAL® platform. The placing is divided into two tranches, with the second tranche contingent on shareholder approval at an upcoming general meeting. This financial move aims to capitalize on growth opportunities and improve the company’s market positioning, particularly in North America, while addressing the need for increased working capital.
More about Fusion Antibodies Plc
Fusion Antibodies plc operates in the biotechnology industry, specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. The company focuses on developing proprietary platforms like OptiMAL® and expanding its presence in key markets such as North America.
YTD Price Performance: -4.26%
Average Trading Volume: 1,226,105
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £6.48M
For a thorough assessment of FAB stock, go to TipRanks’ Stock Analysis page.